Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials

February 5, 2026
, 8:44 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Eikon Therapeutics’ IPO haul will support a lead program that could expand the scope of cancer immunotherapy. Eikon’s stock market debut builds on growing IPO momentum, following upsized offerings from Aktis Oncology and Veradermics.

The post Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials appeared first on MedCity News.

Leave a Replay

Early detection of female-specific cancers using longitudinal healthcare records with a multichannel convolutional neural network

COO of Mayo Clinic Platform Believes De-identified Data Leads to Loss of Utility for Pharma, Other Third Parties

Talkiatry Rakes In $210M to Scale Virtual Psychiatry Group

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials

Leave a Replay

Related Posts

Early detection of female-specific cancers using longitudinal healthcare records with a multichannel convolutional neural network

COO of Mayo Clinic Platform Believes De-identified Data Leads to Loss of Utility for Pharma, Other Third Parties

Talkiatry Rakes In $210M to Scale Virtual Psychiatry Group

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us